Clinical trial guidelines from the drug industry trade group PhRMA, go into effect Oct. 1. They include guidelines that basically ban ghostwriting of reports and stipulate that a doctor who has an ownership stake in a drug cannot be a clinical investigator in a trial of that drug. The guidelines are purely voluntary, however.
Trending:
New pharma guidelines: No ghostwriting, more public info